新冠肺炎疫情专利问题若干思考

Some Thoughts on Patent Issues of Novel Coronavirus Pneumonia Epidemic

新型冠状病毒肺炎疫情引发药品等医疗发明专利问题。对于新型冠状病毒基因序列可专利客体问题,可以采用较为宽松的授权标准,从而鼓励对于病毒的基础性研究和利益分享。在新冠肺炎药品研发领域,应当通过建立专利池促进技术整合、降低交易成本,避免专利丛林问题。在新冠肺炎药品专利实施中,有必要积极通过颁发专利强制许可提高患者以合理价格获得药品的可能性。在新冠肺炎医疗发明专利政策方面,应当与我国发展水平相适应,加强法律制度及行政部门之间的协调配合,进行动态管理并加强国际合作。由此,可以有效解决疫情所带来的专利问题,提高应对疫情的医疗水平并早日消除疫情影响。

The epidemic of Novel Coronavirus Pneumonia(NCP)has caused problems in patent for inventions in the medical field,such as drugs.For the issue of patentable subject matter of novel coronavirus gene sequences,a relatively relaxed authorization standard can be adopted,thereby encouraging basic research and benefit-sharing of the virus.In the field of research and development of NCP drugs,a patent pool should be established to promote technological integration,reduce transaction costs,and avoid problems of patent thickets.In the implementation of NCP medicines patents,it is necessary to actively grant compulsory patent licensing to increase the possibility of patients obtaining medicines at reasonable prices.In terms of patent policy in NCP medicines,it should be compatible with China's development level,strengthen coordination and cooperation between legal regime and administrative departments,conduct dynamic management and strengthen international cooperation.Therefore,it can effectively settle the patent issues brought about by the epidemic,improve the medical level in response to the epidemic and eliminate the epidemic as soon as possible.